Novo Nordisk presents CagriSema REIMAGINE and zenagamtide data at the ADA Scientific Sessions

Novo Nordisk used the American Diabetes Association's 2026 Scientific Sessions in New Orleans, held June 5–8, to show off the next wave of its cardiometabolic pipeline, including Phase 3 REIMAGINE results for CagriSema in type 2 diabetes and Phase 2b results for zenagamtide, the injectable GLP-1/amylin drug formerly called amycretin ^[1]. The company presented 40 abstracts in total ^[1].

The REIMAGINE 1, 2 and 3 results were featured in a dedicated symposium on Sunday, June 7, from 4:30 to 6:00 pm CDT, described as evaluating CagriSema's effects on blood sugar control and weight loss across a range of background type 2 diabetes therapies ^[1]. CagriSema is a once-weekly injection that combines cagrilintide, a long-acting amylin analog, with semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy ^[1]. It is being studied in the REDEFINE program for overweight and obesity and the REIMAGINE program for type 2 diabetes ^[1].

The specific REIMAGINE numbers presented at the symposium are not contained in the sources available here, so the size of the A1C and weight changes by background therapy is not yet known from this material. For context on earlier CagriSema work, a small Phase 2 trial reported a 2.2% mean change in HbA1c and a 15.6% reduction in body weight at 32 weeks, and a Phase 3 trial reported a 13.7% drop in body weight at week 68, with 73.5% of patients reaching an HbA1c of 6.5% or less ^[2].

What the zenagamtide data showed

Zenagamtide was presented in poster 1730-P, "Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D," on Sunday, June 7 ^[1]. Unlike CagriSema's two-ingredient combination, zenagamtide is a single molecule that hits both the GLP-1 and amylin receptors, and Novo is developing both oral and injectable versions ^[1].

When Novo first reported the Phase 2 diabetes topline in November 2025, the trial had enrolled 448 people with type 2 diabetes that was inadequately controlled on metformin, with about 40% also using an SGLT2 inhibitor ^[2]. By week 36, people on the weekly injection had HbA1c reductions of up to 1.8%, compared with 0.2% on placebo, from a mean baseline of 7.8% ^[2]. HbA1c fell below 7% in 89.1% of patients and to 6.5% or lower in 76.2% ^[2]. Weight loss on the injection reached up to 14.5% from a mean baseline of 99.2 kg, versus 2.6% on placebo ^[2]. Novo's own summary of the ADA presentation describes roughly 14.6% weight loss; the sources here differ slightly on that figure, and the exact number from the conference poster is not confirmed in the material available.

The once-daily oral version lowered HbA1c by up to 1.5% versus 0.4% on placebo and produced up to 10.1% weight loss from a mean baseline of 101.1 kg, compared with 2.5% on placebo ^[2]. Side effects were described as the expected mix of mostly mild to moderate gastrointestinal events ^[2]. Novo said weight loss had not plateaued by week 36 at the higher doses ^[2].

Why it matters for patients

None of this changes what is available at a US pharmacy today. CagriSema and zenagamtide are not approved in the United States, and Novo states plainly that their safety and efficacy are not established and there is no guarantee they will reach the market ^[1]. Conference presentations are also not the same as peer-reviewed publication; as of September 2026, neither the REIMAGINE Phase 3 results nor the zenagamtide Phase 2b results had appeared in a peer-reviewed journal, which means independent reviewers have not yet vetted the full data tables.

The broader signal is that amylin-based drugs are moving from obesity into diabetes care, where the goal is both blood sugar control and weight loss. A single-molecule option like zenagamtide could also be simpler to manufacture and deliver in one device, an argument Novo's research chief has made publicly ^[2].

What happens next

Novo said in November 2025 that it would begin Phase 3 development of zenagamtide in type 2 diabetes in 2026 ^[2]. Specific filing timelines for CagriSema in type 2 diabetes are not given in these sources.